secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001213900-21-041160
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus restates 2020 financials; net income rises to $1.4M from $1.1M
---------------------------------------------------------------------

- Non-reliance on FY2020 financials due to equity method investment misstatement; restated 10-K/A filed with unqualified audit opinion.
- Net income restated to $1.4M from $1.1M; increase of $254K and $0.01 EPS from corrected equity in losses of Japanese affiliate EJ Holdings.
- Original audit opinion had qualification; now eliminated with complete audit of affiliate financials.
- Trading on OTC Pink could be suspended if Q1 and Q2 2021 10-Qs not filed by September 28, 2021; company striving to file promptly.
- Interim Endari® sales volumes previously reported; full Q1 and Q2 2021 results expected in upcoming 10-Q filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390021041160/0001213900-21-041160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390021041160/ea145361-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-041160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer